Regado permanantly halts enrollment in lead drug trial

Aug 25 (Reuters) - Regado Biosciences Inc said it stopped enrollment in the late-stage trial for its lead drug after an independent committee recommended raised serious concerns of allergic reactions to the experimental blood thinner.